[go: up one dir, main page]

AR049784A1 - Derivados sustituidos de morfolina y tiomorfolina - Google Patents

Derivados sustituidos de morfolina y tiomorfolina

Info

Publication number
AR049784A1
AR049784A1 ARP050100893A ARP050100893A AR049784A1 AR 049784 A1 AR049784 A1 AR 049784A1 AR P050100893 A ARP050100893 A AR P050100893A AR P050100893 A ARP050100893 A AR P050100893A AR 049784 A1 AR049784 A1 AR 049784A1
Authority
AR
Argentina
Prior art keywords
cycloalkyl
iloc1
iloc3
alkyl
halo
Prior art date
Application number
ARP050100893A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37730781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049784(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR049784A1 publication Critical patent/AR049784A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Reivindicacion 1: Un derivado sustituido de morfolina o tiomorfolina de formula general (1), en el cual: q es 0 o 1; W es O o S; X es CO; Z es O; R1 se selecciona del grupo por halogeno, ciano, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)iloC3-8-alqu(en/in)iloC1-6, halo-alqu(en/in)iloC1-6, halo-cicloalqu(en)iloC3-8, halo-cicloalqu(en)iloC3-8-alqu(en/in)iloC1-6, alqu(en/in)iloxi C1-6, cicloalque(en)iloxi C3-8 y cicloalqu(en)iloC3-8-alqu(en/in)iloxiC1-6; R2 se selecciona del grupo por halogeno, ciano, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)iloC3-8-alqu(en/in)iloC1-6, halo-alqu(en/in)iloC1-6, halo-cicloalqu(en)iloC3-8, halo-cicloalqu(en)iloC3-8-alqu(en/in)iloC1-6, alqu(en/in)iloxi C1-6, cicloalque(en)iloxi C3-8, cicloalqu(en)iloC3-8-alqu(en/in)iloxiC1-6, el fenilo sustituido en forma opcional y el piridilo sustituido en forma opcional; en los que el fenilo y el piridilo están sustituidos en forma opcional con uno o más sustituyentes que son, en forma independiente, halogeno, alqu(en/in)ilo C1-6, cicloaqu(en)ilo C3-8 o cicloalqu(en)iloC3-8-alqu(en/in)iloC1-6; R3 se selecciona del grupo formado por alqu(en/in)iloC1-10, cicloalqu(en)ilo C3-8, cicloalqu(en)iloC3-8- alqu(en/in)iloC1-6, Ar-alqu(en/in)iloC1-6, Ar-cicloaqu(en)iloC3-8, Ar-cicloalqu(en)iloC3-8-alqu(en/in)iloC1-6 y Ar; y cada uno de R4, R5, R6 y R7 se selecciona en forma independiente del grupo formado por hidrogeno y Ar; como base libre o sus sales.
ARP050100893A 2004-03-12 2005-03-08 Derivados sustituidos de morfolina y tiomorfolina AR049784A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55257404P 2004-03-12 2004-03-12
DKPA200400412 2004-03-12

Publications (1)

Publication Number Publication Date
AR049784A1 true AR049784A1 (es) 2006-09-06

Family

ID=37730781

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100893A AR049784A1 (es) 2004-03-12 2005-03-08 Derivados sustituidos de morfolina y tiomorfolina

Country Status (31)

Country Link
US (6) US7501414B2 (es)
EP (3) EP1727809B8 (es)
JP (1) JP5006184B2 (es)
KR (2) KR20120136422A (es)
CN (2) CN1930138A (es)
AR (1) AR049784A1 (es)
AT (2) ATE398112T1 (es)
AU (1) AU2005221762B2 (es)
BR (1) BRPI0508570B8 (es)
CA (1) CA2559397C (es)
CO (1) CO5721001A2 (es)
CY (2) CY1110392T1 (es)
DE (2) DE602005007474D1 (es)
DK (2) DK1727809T3 (es)
EA (1) EA015120B1 (es)
EG (1) EG25344A (es)
ES (2) ES2334076T3 (es)
HR (1) HRP20090685T1 (es)
IL (1) IL177859A (es)
MY (2) MY147786A (es)
NO (1) NO337161B1 (es)
NZ (1) NZ549133A (es)
PL (2) PL1727809T3 (es)
PT (2) PT1727809E (es)
RS (2) RS50606B (es)
SG (1) SG151254A1 (es)
SI (2) SI1727809T1 (es)
TW (2) TWI357901B (es)
UA (2) UA102517C2 (es)
WO (1) WO2005087754A1 (es)
ZA (2) ZA200607286B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI357901B (en) * 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
UA89503C2 (uk) * 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
UA92340C2 (en) * 2005-03-03 2010-10-25 Х. Луннбек А/С Substituted pyridine derivatives
WO2006092143A1 (en) * 2005-03-03 2006-09-08 H. Lundbeck A/S Substituted pyridine derivatives
KR20080096659A (ko) 2006-02-07 2008-10-31 하. 룬트벡 아크티에 셀스카브 정신분열증 증상의 치료 또는 감소를 위한 ｋｃｎｑ개방제의 용도
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
AU2007288253B2 (en) 2006-08-23 2013-05-02 Xenon Pharmaceuticals Inc. Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
BRPI0719590A2 (pt) 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
UA97847C2 (ru) * 2007-08-01 2012-03-26 Х. Луннбек А/С Применение соединений, которые открывают калиевые каналы kcnq, для лечения дефицита внимания/гиперактивности (adhd) или агрессии
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
SG176464A1 (en) * 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
WO2010094645A1 (en) * 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
WO2010094644A1 (en) * 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
TW201041857A (en) * 2009-05-11 2010-12-01 Lundbeck & Co As H Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
US20100286138A1 (en) * 2009-05-11 2010-11-11 H. Lundbeck A/S Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
US20120232058A1 (en) * 2009-09-07 2012-09-13 Neurosearch A/S Substituted pyridine derivatives and their medical use
EP2590961A1 (en) 2010-07-08 2013-05-15 Pfizer Inc Piperidinyl pyrimidine amides as kv7 potassium channel openers
CN103073455B (zh) 2011-10-25 2015-08-19 中国科学院上海药物研究所 一类新型的kcnq钾通道激动剂、其制备方法和用途
EP2844247A4 (en) * 2012-04-20 2015-11-25 Anderson Gaweco ROR MODULATORS AND ITS USES
CN103044431A (zh) * 2012-10-22 2013-04-17 中国药科大学 制备五氟磺草胺的新方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CA2969756A1 (en) * 2014-12-05 2016-06-09 Aquinnah Pharmaceuticals, Inc. Sulfonamide derivatives, compositions and methods of use in the treatment of neurodegenerative diseases
EP3366683A1 (en) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
WO2020157126A1 (en) 2019-01-29 2020-08-06 Università degli Studi di Salerno Modulators of potassium ion channels and uses thereof
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
KR20220098746A (ko) 2019-11-08 2022-07-12 제논 파마슈티칼스 인크. 우울 장애 치료 방법
IL304920A (en) 2021-02-09 2023-10-01 Xenon Pharmaceuticals Inc A voltage-gated potassium channel opener for use in the treatment of anhedonia
IL282188A (en) * 2021-04-08 2022-11-01 Yeda Res & Dev Combined use of ketamine and bretigabine for the treatment of psychiatric disorders
CN116478068A (zh) 2022-01-14 2023-07-25 中国科学院上海药物研究所 一种高选择性kcnq4钾通道激动剂、其制备方法和用途
CN118239907B (zh) * 2024-03-25 2024-09-03 威海天宇新材料科技有限公司 一种橡胶硫化剂dtdm的合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03175086A (ja) * 1989-09-14 1991-07-30 Fuji Photo Film Co Ltd ジアゾ感熱記録材料
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
NZ329200A (en) * 1996-12-16 1999-05-28 Hoechst Ag Sulphonamide substituted quinazoline, isoquinoline, quinoline or benzo[1,3-]oxazine derivatives and medicaments
CZ225699A3 (cs) 1996-12-23 2000-09-13 Du Pont Pharmaceuticals Company Dusíkaté heteroaromatické sloučeniny jako inhibitory faktoru Xa
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
CA2276034A1 (en) * 1996-12-23 1998-07-02 Mimi Lifen Quan Oxygen or sulfur containing 5-membered heteroaromatics as factor xa inhibitors
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
CA2314401A1 (en) 1997-12-22 1999-07-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
CA2321538A1 (en) * 1998-03-27 1999-10-07 Dupont Pharmaceuticals Company Disubstituted pyrazolines and triazolines as factor xa inhibitors
US6326385B1 (en) * 1999-08-04 2001-12-04 Icagen, Inc. Methods for treating or preventing pain
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
JP2003534801A (ja) 2000-05-26 2003-11-25 ブリストル−マイヤーズ スクイブ カンパニー ヒトｋｃｎｑ５カリウムチャンネル、並びにその方法および組成物
WO2001096540A2 (en) 2000-06-11 2001-12-20 Dupont Pharmaceuticals Company Hepatitis c protease exosite for inhibitor design
PE20020044A1 (es) * 2000-06-16 2002-01-30 Upjohn Co Tiazina oxazolidinona
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
CN100384833C (zh) * 2001-01-16 2008-04-30 阿斯特拉曾尼卡有限公司 治疗用苯并二氢吡喃化合物
EP1353914A2 (en) * 2001-01-16 2003-10-22 AstraZeneca AB Therapeutic chromone compounds
CN1250519C (zh) * 2001-01-19 2006-04-12 中国人民解放军军事医学科学院毒物药物研究所 具有调节钾通道功能的胺衍生物及其制备方法和应用
HUP0303841A2 (hu) * 2001-02-20 2004-03-01 Bristol-Myers Squibb Company 2,4-Diszubsztituált-5-pirimidinkarboxamid-származékok mint KCNQ káliumcsatorna modulátorok és ezeket tartalmazó gyógyszerkészítmények és előállításuk
SE0103648D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
SE0103649D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati

Also Published As

Publication number Publication date
NO20064599L (no) 2006-12-08
HRP20090685T1 (hr) 2010-02-28
DE602005007474D1 (en) 2008-07-24
DE602005016849D1 (de) 2009-11-05
ATE443702T1 (de) 2009-10-15
BRPI0508570B8 (pt) 2021-05-25
EA015120B1 (ru) 2011-06-30
SI1947093T1 (sl) 2010-01-29
US20060167248A1 (en) 2006-07-27
AU2005221762B2 (en) 2011-06-09
EP1947093B1 (en) 2009-09-23
ATE398112T1 (de) 2008-07-15
CN1930138A (zh) 2007-03-14
ZA200607286B (en) 2008-04-30
PT1947093E (pt) 2009-12-22
UA90670C2 (en) 2010-05-25
ES2334076T3 (es) 2010-03-04
SG151254A1 (en) 2009-04-30
CN102516204A (zh) 2012-06-27
DK1727809T3 (da) 2008-09-29
EP1727809B1 (en) 2008-06-11
TWI357901B (en) 2012-02-11
TW200533359A (en) 2005-10-16
US20100063033A1 (en) 2010-03-11
US20090137571A1 (en) 2009-05-28
EP1947093B9 (en) 2010-03-03
PT1727809E (pt) 2008-08-13
EA200601686A1 (ru) 2007-02-27
EG25344A (en) 2011-12-14
BRPI0508570B1 (pt) 2018-11-21
HK1172618A1 (zh) 2013-04-26
CA2559397C (en) 2010-08-10
JP2007528880A (ja) 2007-10-18
US7812023B2 (en) 2010-10-12
MY143698A (en) 2011-06-30
IL177859A (en) 2013-02-28
US7632835B2 (en) 2009-12-15
KR20060128004A (ko) 2006-12-13
SI1727809T1 (sl) 2008-10-31
KR20120136422A (ko) 2012-12-18
MY147786A (en) 2013-01-31
EP1727809B8 (en) 2008-10-29
TWI349666B (en) 2011-10-01
NO337161B1 (no) 2016-02-01
UA102517C2 (ru) 2013-07-25
US20110294787A1 (en) 2011-12-01
TW200811121A (en) 2008-03-01
ES2306087T3 (es) 2008-11-01
EP1947093A1 (en) 2008-07-23
US20090143369A1 (en) 2009-06-04
CO5721001A2 (es) 2007-01-31
AU2005221762A1 (en) 2005-09-22
PL1947093T3 (pl) 2010-02-26
RS51066B (sr) 2010-10-31
RS50606B (sr) 2010-05-07
CY1109656T1 (el) 2014-08-13
CA2559397A1 (en) 2005-09-22
IL177859A0 (en) 2006-12-31
EP1727809A1 (en) 2006-12-06
US20100063036A1 (en) 2010-03-11
WO2005087754A1 (en) 2005-09-22
US8012962B2 (en) 2011-09-06
US8299075B2 (en) 2012-10-30
KR101411204B1 (ko) 2014-06-23
NZ549133A (en) 2010-09-30
US7501414B2 (en) 2009-03-10
PL1727809T3 (pl) 2008-11-28
BRPI0508570A (pt) 2007-08-14
CN102516204B (zh) 2016-01-20
JP5006184B2 (ja) 2012-08-22
EP2138487A1 (en) 2009-12-30
ZA200709718B (en) 2008-09-25
DK1947093T3 (da) 2010-02-01
CY1110392T1 (el) 2015-04-29

Similar Documents

Publication Publication Date Title
AR049784A1 (es) Derivados sustituidos de morfolina y tiomorfolina
CR9783A (es) Inhibidores macrociclicos del virus de la hepatitis c
ECSP099395A (es) Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico
ECSP077274A (es) Derivados de n-2 adamantanil-2-fenoxi-acetamida como inhibidores de deshidrogenasa 11-beta hidroxiesteroide
CO6321244A2 (es) Pirrolopiridinas como inhibidores de cinasa
EA201170096A1 (ru) Замещенные производные пиримидона
ECSP11010912A (es) Compuestos de pirrol
CR8264A (es) Derivados de malonamida bloqueadores de la actividad gamma-secretase
CU20100021A7 (es) Derivado de oxopirazina y herbicida
PE20050676A1 (es) Quinolinas referidas a enfermedades cardiovasculares
ES2308299T3 (es) Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas.
AR054130A1 (es) Procedimiento para la preparacion de 1-alquil-3-feniluracilos
PE20080068A1 (es) Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
AR066606A1 (es) Compuestos de heteroarilamida pirimidona
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
CO6150147A2 (es) Derivados de 5,6-bisaril-2-piridin-carboxamida su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
AR050266A1 (es) Derivados de bencil-triazolona como inhibidores no nucleosidos de transcriptasa inversa
AR066603A1 (es) Derivados de arilamida pirimidona
CO6160324A2 (es) Heterociclos sustituidos que contienen nitrogeno como inhibidores del receptor adp plaquetario
CO2017003830A2 (es) Compuestos de piridina
CO6290665A2 (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina
AR039122A1 (es) Derivados de ftalimido como inhibidores de monoamino oxidasa b
TW200517387A (en) Compounds exhibiting thrombopoietin receptor agonism
AR075245A1 (es) Derivados de fenilimidazol utiles en el tratamiento de la hiperlipidemia y obesidad, y composiciones farmaceuticas que los contienen.
CO5650235A2 (es) Derivados de imidazol

Legal Events

Date Code Title Description
FG Grant, registration